Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)

Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.

Trial Locations (1)

119074

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT01482754 - Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter